US2007299059A1PendingUtilityA1
Compostions and methods relating to novel compounds and targets thereof
Est. expiryApr 30, 2019(expired)· nominal 20-yr term from priority
C07D 403/12A61K 31/551A61P 43/00C07D 243/24A61K 31/5513C07D 413/12C07D 243/14C07D 401/12
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
Claims
exact text as granted — not AI-modified1 - 19 . (canceled)
20 . A composition comprising a benzodiazepine compound described by the following formula:
including salts and both R and S enantiomeric forms and racemic mixtures thereof;
wherein R 1 is selected from the group consisting of a hydrogen, alkyl, and a substituted alkyl;
wherein R 2 is halogen;
wherein R 3 is a substituted aromatic group; and
wherein R 4 is selected from the group consisting of halogen, alkyl and a substituted alkyl.
21 . The composition of claim 20 , wherein R 2 is chlorine.
22 . The composition of claim 20 , wherein R 1 is a H or a CH 3 .
23 . The composition of claim 20 , wherein R 3 is selected from the group consisting of:
24 . The composition of claim 20 , wherein said compound is described by a formula selected from the group consisting of:
wherein R 4 is hydrogen, alkyl, or substituted alkyl; and
wherein R 5 is OH, N 3 , OCH 3 , alkyl or substituted alkyl.
25 . The composition of claim 20 , wherein R 4 is selected from the group consisting of: (CH 2 ) n C(CH 3 ) 3 , (CH 2 ) n CH(CH 3 ) 2 , CH 2 (CH 2 ) n CH 3 , di-alkyl, di-fluoromethyl, t-butyl, di-halogen, and di-methyl; wherein n=0-5.
26 . The composition of claim 20 , wherein said compound is described by a formula selected from the group consisting of:
wherein R 1 is hydrogen, alkyl, or substituted alkyl;
wherein R 2 is halogen;
wherein R 3 is selected from the group consisting of:
27 . A pharmaceutical composition comprising a benzodiazepine of any one of claim 20 and a pharmaceutically acceptable carrier.
28 . A pharmaceutical composition comprising a benzodiazepine of any one of claim 21 and a pharmaceutically acceptable carrier.
29 . A pharmaceutical composition comprising a benzodiazepine of any one of claim 22 and a pharmaceutically acceptable carrier.
30 . A pharmaceutical composition comprising a benzodiazepine of any one of claim 23 and a pharmaceutically acceptable carrier.
31 . A pharmaceutical composition comprising a benzodiazepine of any one of claim 24 and a pharmaceutically acceptable carrier.
32 . A pharmaceutical composition comprising a benzodiazepine of any one of claim 25 and a pharmaceutically acceptable carrier.
33 . A pharmaceutical composition comprising a benzodiazepine of any one of claim 26 and a pharmaceutically acceptable carrier.
34 . A method of treating a disorder selected from the group consisting of an immune disorder, a hyperproliferative disorder, and a chronic inflammatory condition, comprising administering an effective amount of a benzodiazepine compound to a subject suffering from said immune disorder, said hyperproliferative disorder, or said chronic inflammatory condition, wherein said benzodiazepine compound comprises the following formula:
including salts and both R and S enantiomeric forms and racemic mixtures;
wherein R 1 is selected from the group consisting of a hydrogen, alkyl, and a substituted alkyl;
wherein R 2 is halogen;
wherein R 3 is a substituted aromatic group; and
wherein R 4 is selected from the group consisting of halogen, alkyl and a substituted alkyl.
35 . The method of claim 34 , wherein R 2 is chlorine.
36 . The method of claim 34 , wherein R 1 is a H or a CH 3 .
37 . The method of claim 34 , wherein R 3 is selected from the group consisting of:
38 . The method of claim 34 , wherein said compound is described by a formula selected from the group consisting of:
wherein R 4 is hydrogen, alkyl, or substituted alkyl; and
wherein R 5 is OH, N 3 , OCH 3 , alkyl or substituted alkyl.
39 . The method of claim 34 , wherein R 4 is selected from the group consisting of: (CH 2 ) n C(CH 3 ) 3 , (CH 2 ) n CH(CH 3 ) 2 , CH 2 (CH 2 ) n CH 3 , di-alkyl, di-fluoromethyl, t-butyl, di-halogen, and di-methyl; wherein n=0-5.
40 . The method of claim 34 , wherein said compound is described by a formula selected from the group consisting of:
wherein R 1 is hydrogen, alkyl, or substituted alkyl;
wherein R 2 is halogen;
wherein R 3 is selected from the group consisting of:
41 . The method of claim 34 , wherein said compound is described by a formula selected from the group consisting of:
wherein R 1 is hydrogen, alkyl, or substituted alkyl;
wherein R 2 is halogen;
wherein R 3 is selected from the group consisting of:
42 . The method of claim 34 , wherein the disorder is an immune disorder selected from the group consisting of graft versus host disease, rheumatoid arthritis, and systemic lupus erythematosus.
43 . The method of claim 38 , wherein the disorder is an immune disorder selected from the group consisting of graft versus host disease, rheumatoid arthritis, and systemic lupus erythematosus.
44 . The method of claim 34 , wherein the disorder is a cancer.
45 . The method of claim 38 , wherein the disorder is a cancer.
46 . The method of claim 44 , wherein the cancer is a tumor, a neoplasm, a lymphoma, or a leukemia.
47 . The method of claim 45 , wherein the cancer is a tumor, a neoplasm, a lymphoma, or a leukemia.
48 . The method of claim 34 , wherein the disorder is a chronic inflammatory condition selected from the group consisting of asthma and psoriasis.
49 . The method of claim 38 , wherein the disorder is a chronic inflammatory condition selected from the group consisting of asthma and psoriasis.
50 . The method of claim 42 , further comprising administering an additional agent for treating said immune disorder.
51 . The method of claim 43 , further comprising administering an additional agent for treating said immune disorder.
52 . The method of claim 44 , further comprising administering an additional agent for treating said cancer.
53 . The method of claim 45 , further comprising administering an additional agent for treating said cancer.
54 . The method of claim 48 , further comprising administering an additional agent for treating said chronic inflammatory condition.
55 . The method of claim 49 , further comprising administering an additional agent for treating said chronic inflammatory condition.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.